Fredun Pharmaceuticals Ltd
Incorporated in 1987, Fredun Pharmaceuticals
Ltd manufactures & exports healthcare and pharmaceuticals products[1]
- Market Cap ₹ 345 Cr.
- Current Price ₹ 731
- High / Low ₹ 956 / 635
- Stock P/E 17.5
- Book Value ₹
- Dividend Yield 0.10 %
- ROCE %
- ROE %
- Face Value ₹ 10.0
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | |
|---|---|
| 454 | |
| 401 | |
| Operating Profit | 52 |
| OPM % | 12% |
| 2 | |
| Interest | 22 |
| Depreciation | 5 |
| Profit before tax | 27 |
| Tax % | 28% |
| 20 | |
| EPS in Rs | 41.81 |
| Dividend Payout % | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 32% |
| 3 Years: | -5% |
| 1 Year: | -6% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | |
|---|---|
| Equity Capital | |
| Reserves | |
| Total Liabilities | |
| CWIP | |
| Investments | |
| Total Assets |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | |
|---|---|
| -29 | |
| -6 | |
| 39 | |
| Net Cash Flow | 4 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | |
|---|---|
| Debtor Days | |
| Inventory Days | |
| Days Payable | |
| Cash Conversion Cycle | |
| Working Capital Days | |
| ROCE % |
Documents
Announcements
-
Revised Outcome Of The Board Meeting Dated 30.05.2025
31 May - Fredun Pharma reports FY25 audited results; net profit Rs 2080.76L, recommends 7% final dividend.
-
Standalone And Consolidated Audited Financial Results For The Quarter And Financial Year Ended March 31, 2025 Along With Statement Of Assets And Liabilities And Cash Flow Statement
31 May - Fredun Pharma reports FY25 audited results; net profit Rs 2080.76L; recommends 7% final dividend.
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
31 May - Fredun reports 30.7% revenue growth, new veterinary products, international petcare launch, and Rs. 150-180 mn tender win.
-
Announcement under Regulation 30 (LODR)-Change in Management
31 May - Re-appointment of secretarial auditor and appointment of internal and cost auditors for FY 2025-26.
-
Standalone And Consolidated Financial Results For The Period Ended On 31St March 2025.
31 May - Fredun Pharmaceuticals reports FY25 audited results; recommends 7% final dividend; auditor unmodified opinion.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
Business Overview:[1]
Company is a subsidiary of Fredun Group. It manufactures pharmaceutical and allopathic formulations viz. tablets, syrups, capsules, and ointments. Product basket includes multiple therapeutic classes such as anti-diabetics, anti-retroviral and anti-hypertensive. Company also ventured into manufacturing of dietary/herbal supplements, neutraceuticals, diagnostic kits along with Animal Healthcare products through its group companies Fredun Healthcare Pvt. Ltd. & Fredna Entereprises.
Company has 23 therapeutic classes*(including anti-diabetics, anti-retroviral
and anti-hypertensive), with 450** products registered in overseas markets.